These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Crim C; Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Lettis S; Calverley PM Ann Am Thorac Soc; 2015 Jan; 12(1):27-34. PubMed ID: 25490706 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies. Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292 [TBL] [Abstract][Full Text] [Related]
24. Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. Adamson PD; Anderson JA; Brook RD; Calverley PMA; Celli BR; Cowans NJ; Crim C; Dixon IJ; Martinez FJ; Newby DE; Vestbo J; Yates JC; Mills NL J Am Coll Cardiol; 2018 Sep; 72(10):1126-1137. PubMed ID: 30165984 [TBL] [Abstract][Full Text] [Related]
25. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R; BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562 [TBL] [Abstract][Full Text] [Related]
26. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Vestbo J; Anderson J; Brook RD; Calverley PM; Celli BR; Crim C; Haumann B; Martinez FJ; Yates J; Newby DE Eur Respir J; 2013 May; 41(5):1017-22. PubMed ID: 23018908 [TBL] [Abstract][Full Text] [Related]
30. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013. Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371 [TBL] [Abstract][Full Text] [Related]
32. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. Vestbo J; Leather D; Diar Bakerly N; New J; Gibson JM; McCorkindale S; Collier S; Crawford J; Frith L; Harvey C; Svedsater H; Woodcock A; N Engl J Med; 2016 Sep; 375(13):1253-60. PubMed ID: 27593504 [TBL] [Abstract][Full Text] [Related]
34. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma. Braithwaite I; Williams M; Power S; Pilcher J; Weatherall M; Baines A; Moynihan J; Kempsford R; Beasley R; Respir Med; 2016 Oct; 119():115-121. PubMed ID: 27692131 [TBL] [Abstract][Full Text] [Related]
35. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Nannini L; Cates CJ; Lasserson TJ; Poole P Cochrane Database Syst Rev; 2004; (3):CD003794. PubMed ID: 15266502 [TBL] [Abstract][Full Text] [Related]
36. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Farne HA; Cates CJ Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945 [TBL] [Abstract][Full Text] [Related]
37. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586 [TBL] [Abstract][Full Text] [Related]
38. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Yates JC; Vestbo J; N Engl J Med; 2007 Feb; 356(8):775-89. PubMed ID: 17314337 [TBL] [Abstract][Full Text] [Related]
39. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448 [TBL] [Abstract][Full Text] [Related]
40. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]